NCT01318317View on ClinicalTrials.gov

Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 19, 2011

Primary Completion Date

October 3, 2013

Study Completion Date

February 26, 2026

Conditions
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin Lymphoma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous PBSCT

BIOLOGICAL

Filgrastim

Given IV

BIOLOGICAL

Genetically Engineered Lymphocyte Therapy

Receive ex vivo expanded autologous TCM-enriched CD8+ T cells expressing CD19-specific CAR

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous PBSCT

DRUG

Plerixafor

Given IV

BIOLOGICAL

Rituximab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01318317 - Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter